Thermo acquire Sterilin and Phadia

Thermo Fisher Scientific has acquired Sterilin – a provider of consumable products for microbiology – and Phadia, a global allergy and autoimmunity diagnostics firm.

The acquisition of Sterilin included a broad portfolio of single-use laboratory products used in sample collection, storage and analysis including petri dishes, specimen containers and serological pipettes.

“The acquisition of Sterilin allows us to expand our sample collection portfolio, we can now provide a broader range of high-quality products for any microbiological, clinical and general life sciences workflow, from sample collection and processing through to analysis,” said Chuck Kummeth, president of lab consumables at Thermo Fisher.

Thermo Fisher has acquired Phadia from Cinven for $3.5bn in cash, with the transaction expected to be complete in Q4 of 2011. Phadia develop, manufacture and market complete blood test systems to support clinical diagnosis and monitoring of allergy and autoimmune diseases.

“The acquisition of Phadia is a major step forward in our strategy to enhance Thermo Fisher’s global presence in speciality diagnostics, one of our key growth platforms,” said Marc N Cooper, president and CEO of Thermo Fisher. “This transaction will provide Thermo Fisher with leading allergy and autoimmunuty diagnostic testing technologies that expand our speciality diagnostics offerings.”